These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27986997)

  • 1. Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study.
    Lin HL; Lin HC; Tseng YF; Chen SC; Hsu CY
    Eur J Clin Pharmacol; 2017 Mar; 73(3):365-371. PubMed ID: 27986997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine.
    Fabiani G; Pastro PC; Froehner C
    Arq Neuropsiquiatr; 2004 Sep; 62(3B):784-8. PubMed ID: 15476069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine.
    Jhang KM; Huang JY; Nfor ON; Tung YC; Ku WY; Lee CT; Liaw YP
    Eur J Clin Pharmacol; 2017 Jul; 73(7):911-916. PubMed ID: 28386684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine.
    Miguel R; Correia AS; Bugalho P
    J Parkinsons Dis; 2014; 4(4):645-9. PubMed ID: 25125483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism.
    Negrotti A; Calzetti S
    Mov Disord; 1997 Jan; 12(1):107-10. PubMed ID: 8990063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis.
    Teive HA; Troiano AR; Germiniani FM; Werneck LC
    Parkinsonism Relat Disord; 2004 Jun; 10(4):243-5. PubMed ID: 15120099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flunarizine and the risk of parkinsonism in a newly diagnosed type 2 diabetic population in Taiwan: A nested case-control study.
    Liang CY; Yeh YC; Lee CJ; Chen YY
    J Clin Neurosci; 2018 Apr; 50():281-286. PubMed ID: 29396059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flunarizine and cinnarizine-induced parkinsonism: 25 years of de Melo-Souza's syndrome.
    Teive HA; Munhoz RP; Ferraz HB
    Arq Neuropsiquiatr; 2009 Sep; 67(3B):957. PubMed ID: 19838540
    [No Abstract]   [Full Text] [Related]  

  • 9. Flunarizine- and cinnarizine-induced extrapyramidal reactions.
    Micheli F; Pardal MF; Gatto M; Torres M; Paradiso G; Parera IC; Giannaula R
    Neurology; 1987 May; 37(5):881-4. PubMed ID: 3574697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permanent non-progressive cinnarizine and flunarizine-induced parkinsonism: An under-recognized tardive syndrome in the elderly?
    Calzetti S; Negrotti A
    J Neurol Sci; 2023 Jan; 444():120526. PubMed ID: 36584558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility.
    Negrotti A; Calzetti S; Sasso E
    Neurotoxicology; 1992; 13(1):261-4. PubMed ID: 1508427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine.
    Capellà D; Laporte JR; Castel JM; Tristán C; Cos A; Morales-Olivas FJ
    BMJ; 1988 Sep; 297(6650):722-3. PubMed ID: 3147743
    [No Abstract]   [Full Text] [Related]  

  • 13. Movement disorders and depression due to flunarizine and cinnarizine.
    Micheli FE; Pardal MM; Giannaula R; Gatto M; Parera I; Paradiso G; Torres M; Pikielny R; Pardal J
    Mov Disord; 1989; 4(2):139-46. PubMed ID: 2733706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study.
    Brücke T; Wöber C; Podreka I; Wöber-Bingöl C; Asenbaum S; Aull S; Wenger S; Ilieva D; Harasko-van der Meer C; Wessely P
    J Cereb Blood Flow Metab; 1995 May; 15(3):513-8. PubMed ID: 7714010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Useless drugs are not placebos: lessons from flunarizine and cinnarizine.
    Laporte JR; Capella D
    Lancet; 1986 Oct; 2(8511):853-4. PubMed ID: 2876292
    [No Abstract]   [Full Text] [Related]  

  • 16. The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
    Munhoz RP; Werneck LC; Teive HA
    Clin Neurol Neurosurg; 2010 Jun; 112(5):431-5. PubMed ID: 20347518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Drug Exposure and Occurrence of Parkinsonism in Korea: A Population-Based Case-Control Study.
    Kim S; Cheon SM; Suh HS
    Ann Pharmacother; 2019 Nov; 53(11):1102-1110. PubMed ID: 31216861
    [No Abstract]   [Full Text] [Related]  

  • 18. Extrapyramidal symptoms associated with calcium-channel blockers.
    Daniel JR; Mauro VF
    Ann Pharmacother; 1995 Jan; 29(1):73-5. PubMed ID: 7711350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine.
    Chouza C; Scaramelli A; Caamaño JL; De Medina O; Aljanati R; Romero S
    Lancet; 1986 Jun; 1(8493):1303-4. PubMed ID: 2872433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine.
    Meyboom RH; Ferrari MD; Dieleman BP
    Lancet; 1986 Aug; 2(8501):292. PubMed ID: 2874317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.